Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor‐Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy

BACKGROUND: The combination of everolimus (EVE) and exemestane (EXE) is approved for the treatment of patients with metastatic hormone receptor‐positive breast cancer (mHRBC) who progress on nonsteroidal aromatase inhibitor (NSAI) therapy. However, none of the patients enrolled in the trial that led...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncologist
Prif Awduron: Cook, Madeline M., Al Rabadi, Luai, Kaempf, Andy J., Saraceni, Megan M., Savin, Michael A., Mitri, Zahi I.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons, Inc. 2020
Pynciau:
Breast Cancer
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873317/
https://ncbi.nlm.nih.gov/pubmed/33230905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13609
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg